NasdaqGS - Nasdaq Real Time Price • USD
Ascendis Pharma A/S (ASND)
As of 3:48 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | -- | -- | 1960 |
| Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | -- | -- | 1974 |
| Ms. Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | -- | -- | 1961 |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | -- | -- | 1971 |
| Mr. Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | -- | -- | -- |
| Mr. Timothy J. Lee | Senior Director of Investor Relations | -- | -- | -- |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | -- | -- | 1961 |
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | -- | -- | 1979 |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology | -- | -- | 1974 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | -- | -- | 1969 |
Ascendis Pharma A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 879
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Corporate Governance
Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- May 02, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 24, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 10, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 27, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 14, 20246-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 02, 2024
Ascendis Pharma A/S Earnings Call
Related Tickers
PCVX Vaxcyte, Inc.
65.08
-0.17%
LEGN Legend Biotech Corporation
43.06
-0.42%
ARGX argenx SE
360.79
-3.69%
GMAB Genmab A/S
29.15
+1.07%
BPMC Blueprint Medicines Corporation
106.80
+0.09%
KRYS Krystal Biotech, Inc.
155.50
+0.47%
CYTK Cytokinetics, Incorporated
58.64
-5.57%
KROS Keros Therapeutics, Inc.
54.28
+0.02%
APGE Apogee Therapeutics, Inc.
52.89
-0.62%
BGNE BeiGene, Ltd.
161.77
+0.39%